ATLANTA — Inhibitex Inc. announced Jan. 11 that its collaborator, Pfizer Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine in healthy adults.
The SA3Ag vaccine contains an antigen originating from the company’s MSCRAMM protein platform. The company licensed its MSCRAMM protein platform to Wyeth (acquired by Pfizer in 2009) on an exclusive worldwide basis for the development of active vaccines against staphylococcus in 2001.
Pfizer is responsible for all clinical development, manufacturing and marketing of the vaccine. Inhibitex, based in Alpharetta, Ga., is eligible to receive a payment upon the achievement of this and future regulatory milestones, as well as royalties on future net sales.